Cannabidiol (CBD) Market
By Source;
Hemp and MarijuanaBy Product;
CBD Oil, CBD Isolates and OthersBy Sales Type;
B2B and B2CBy End-use;
Medical and Personal UseBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).Cannabidiol (CBD) Market Overview
Cannabidiol (CBD) Market (USD Million)
Cannabidiol (CBD) Market was valued at USD 6,453.95 million in the year 2024. The size of this market is expected to increase to USD 59,484.69 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 37.3%.
Cannabidiol (CBD) Market
*Market size in USD million
CAGR 37.3 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 37.3 % |
Market Size (2024) | USD 6,453.95 Million |
Market Size (2031) | USD 59,484.69 Million |
Market Concentration | Low |
Report Pages | 320 |
Major Players
- ENDOCA
- Cannoid, LLC
- Medical Marijuana, Inc.
- Folium Europe B.V.
- Canopy Growth Corporation
- Elixinol
- NuLeaf Naturals, LLC
- Isodiol International, Inc.
- PharmaHemp
- The Cronos Group
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Cannabidiol (CBD) Market
Fragmented - Highly competitive market without dominant players
The Cannabidiol (CBD) Market is gaining strong traction as consumers increasingly pursue natural alternatives to conventional treatments. The demand for CBD-infused products is rising among individuals managing issues like stress, pain, and insomnia. An estimated 68% of users are driven by wellness goals, highlighting the mainstream appeal of CBD in personal health routines.
Greater Awareness Fueling Market Uptake
Awareness of CBD's health benefits continues to grow, pushing adoption across a broader demographic. Around 57% of consumers believe CBD helps reduce inflammation and promote calmness. This rising confidence is reshaping buying behavior, as more individuals turn to holistic, nature-based solutions.
Regulatory Clarity Enhances Trust
Better-defined CBD regulations are enabling safer product development and fostering brand credibility. About 52% of manufacturers have increased compliance efforts, focusing on product quality and safety. These regulatory improvements are encouraging both investors and consumers to engage more actively with the CBD space.
Consumer Behavior Driving Growth
As preferences shift toward non-addictive, plant-based therapies, CBD is gaining traction as a viable alternative to pharmaceuticals. Nearly 61% of users have reported reducing dependence on synthetic medications after regular CBD usage. This trend reflects a broader move toward natural wellness, sustaining growth in the CBD market.
Cannabidiol (CBD) Market Recent Developments
-
In January 2023, Medical Marijuana, Inc. revealed that its subsidiary, HempMeds Brasil, had introduced two new full-spectrum products in Brazil, with concentrations ranging from 3,000-6,000 mg and available in 30 mL and 60 mL jars.
-
In October 2022, Medical Marijuana, Inc. announced that its subsidiary, HempMeds Mexico, had collaborated with the Autonomous University of Barcelona, Spain, and the Meritorious Autonomous University of Puebla, Mexico, to conduct a study demonstrating the benefits of CBD in treating Parkinson’s disease.
-
In October 2022, High Tide, Inc. launched multi-cannabinoid products through its subsidiary, NuLeaf Naturals, in Ontario, Canada. The products listed for sale include Full Spectrum Hemp Multicannabinoid oil and plant-based softgels containing delta-9 tetrahydrocannabinol, cannabichromene, cannabidiol, cannabigerol, and cannabinol.
-
In September 2022, Kannaway, a subsidiary of Medical Marijuana, Inc., announced a distribution agreement with Complete Hemp Technologies (CHT) to expand its capabilities in Europe. Under the agreement, CHT added warehousing and daily operations to the services it already provides to Kannaway in the region.
-
In January 2022, Elixinol launched two innovative CBD products - the Sleep Rapid Rest Liposome and Sleep Gummies - designed to support sleep. The former contains a customized formula of CBN (cannabinol), CBD, chamomile, and lemon balm, while the latter contains 2mg CBN and 15mg CBD.
Cannabidiol (CBD) Market Segment Analysis
In this report, the Cannabidiol (CBD) Market has been segmented by Source, Sales, End-User, and Geography.
Cannabidiol (CBD) Market, By Source
The Cannabidiol (CBD) Market has been segmented by Source into Hemp and Marijuana.
Hemp
Hemp-derived CBD dominates the global market, accounting for approximately 62% of total revenue. This is primarily due to its low THC content, which ensures legal compliance in many countries. Hemp CBD is widely used in wellness products such as oils, tinctures, edibles, and skincare, making it a preferred source among manufacturers and consumers alike.
Marijuana
Marijuana-derived CBD holds a smaller yet significant market share of around 38%. It is preferred for therapeutic applications where a higher concentration of THC and CBD is desired, especially in regions where medical cannabis is legalized. Despite regulatory restrictions in several countries, the segment continues to grow with increased acceptance of medical marijuana programs.
Cannabidiol (CBD) Market, By Sales
The Cannabidiol (CBD) Market has been segmented by Sales into into B2B and B2C.
B2BThe B2B segment dominates the CBD market, contributing nearly 57% of total sales. This growth is driven by bulk purchasing from wholesalers, contract manufacturers, and private-label brands. B2B channels are essential for the supply of raw CBD extracts and finished formulations to retail businesses and medical institutions.
B2CThe B2C segment is rapidly expanding, holding around 43% of the market share. Increased access to CBD products online and in retail stores has fueled direct consumer demand. Consumers are drawn to wellness-focused products like edibles, oils, and skincare, which are marketed directly through brand websites and e-commerce platforms.
Cannabidiol (CBD) Market, By End User
The Cannabidiol (CBD) Market has been segmented by End User into Medical, Personal Use, Pharmaceuticals, and Wellness.
Medical
The medical segment leads the end-user landscape, accounting for approximately 34% of the CBD market. CBD is increasingly used for managing chronic pain, neurological disorders, and inflammatory conditions. Clinical acceptance and ongoing trials are fueling its adoption within regulated healthcare environments.
Personal Use
Personal use of CBD holds nearly 28% of the market share, supported by growing consumer interest in natural remedies and self-care. Consumers often purchase CBD oils, capsules, and edibles for relaxation, stress relief, and sleep support. E-commerce channels are a major driver in this segment’s expansion.
Pharmaceuticals
The pharmaceutical segment represents around 20% of the market, fueled by increasing research into CBD-based prescription drugs. Products like epilepsy treatments and other regulated applications are driving clinical interest. Regulatory approvals and partnerships with biotech firms are shaping the future of this segment.
Wellness
CBD's use in wellness applications is growing steadily, contributing nearly 18% to market share. Popular in topicals, nutraceuticals, and beauty supplements, CBD is associated with holistic health trends. The segment is driven by lifestyle consumers seeking plant-based, non-psychoactive health solutions.
Cannabidiol (CBD) Market, By Geography
In this report, the Cannabidiol (CBD) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Regions and Countries Analyzed in this Report
Cannabidiol (CBD) Market Share (%), by Geographical Region
North America
North America holds the largest share in the global CBD market, contributing nearly 41% of the total revenue. The region benefits from legalized cannabis regulations, high consumer awareness, and the presence of leading CBD manufacturers. The U.S. leads the market due to a growing demand for wellness and therapeutic products.
Europe
Europe represents approximately 28% of the global CBD market, driven by rising demand for natural health supplements and growing acceptance of hemp-based products. Countries like Germany and the UK are key contributors due to favorable regulatory frameworks and increasing public interest in alternative therapies.
Asia Pacific
The Asia Pacific region is witnessing rapid growth, capturing around 15% of the CBD market. Emerging economies such as China, Japan, and South Korea are experiencing rising interest in plant-based wellness solutions. Expanding e-commerce platforms and changing consumer attitudes toward CBD are driving regional expansion.
Middle East & Africa
Middle East and Africa account for nearly 9% of the market, with limited but gradually improving acceptance of CBD-infused products. Regulatory challenges persist, yet countries like South Africa and the UAE are exploring opportunities in the therapeutic cannabis space.
Latin America
Latin America holds a market share of about 7%, with countries like Brazil, Mexico, and Colombia showing increased openness to CBD legalization. The region is benefiting from advancements in medical cannabis laws and a growing focus on alternative health products.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Cannabidiol (CBD) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Growing Consumer Awareness and Acceptance
- Increasing Scientific Research and Clinical Trials
-
Rising Demand for Natural and Organic Wellness Solutions - The Consumers are increasingly prioritizing products derived from natural sources and free from synthetic additives, chemicals, and pesticides. CBD products, being plant-based and derived from the hemp plant, resonate well with this trend towards natural and organic solutions. The inherent perception of CBD as a natural remedy for various health issues, coupled with its minimal processing and organic origins, appeals to health-conscious consumers seeking alternatives to conventional pharmaceuticals. As individuals become more conscious of the potential adverse effects associated with synthetic medications, they are turning towards CBD as a safer, more holistic wellness solution.
The growing awareness of the potential health benefits offered by CBD is driving consumer interest and adoption. Scientific research and anecdotal evidence suggest that CBD may offer a wide range of therapeutic effects, including relief from chronic pain, anxiety, insomnia, and inflammation. As consumers seek alternative remedies for managing various health conditions, CBD products are gaining popularity for their purported therapeutic properties. Additionally, the increasing acceptance of CBD by healthcare professionals and regulatory authorities is bolstering consumer confidence in the safety and efficacy of CBD-based products. This growing recognition of CBD as a natural, non-intoxicating substance with potential health benefits is fueling the demand for CBD products as part of holistic wellness regimens.
Restraints:
- Development of Pharmaceutical-Grade CBD Products
- Delivery Method Advancements
-
Improved Cultivation Practices - Improved cultivation practices present significant opportunities for the CBD (Cannabidiol) industry. By adopting advanced cultivation techniques, such as hydroponics, aeroponics, and vertical farming, CBD producers can optimize plant growth, increase yields, and enhance the quality of their harvests. These modern cultivation methods offer precise control over environmental factors such as temperature, humidity, light, and nutrient levels, leading to healthier and more robust hemp plants. Additionally, the use of sustainable cultivation practices, including organic farming methods and renewable energy sources, can appeal to environmentally conscious consumers and contribute to a positive brand image for CBD companies.
Advancements in genetics and breeding techniques offer opportunities to develop hemp cultivars with desirable traits, such as higher CBD content, disease resistance, and faster growth rates. Through selective breeding and genetic engineering, researchers can tailor hemp varieties to meet the specific needs of CBD producers and consumers. For instance, breeding programs focused on increasing CBD levels while reducing THC (tetrahydrocannabinol) content can lead to the development of hemp strains that comply with regulatory standards and are well-suited for CBD extraction. The emergence of tissue culture technology allows for the rapid propagation of elite hemp clones, ensuring genetic uniformity and consistency in CBD production. Improved cultivation practices hold immense potential for driving innovation, efficiency, and sustainability within the CBD industry, positioning it for long-term growth and success.
Opportunities:
- Development of Pharmaceutical-Grade CBD Products
- Delivery Method Advancements
-
Improved Cultivation Practices - Improved cultivation practices present significant opportunities for the CBD (Cannabidiol) industry. By adopting advanced cultivation techniques, such as hydroponics, aeroponics, and vertical farming, CBD producers can optimize plant growth, increase yields, and enhance the quality of their harvests. These modern cultivation methods offer precise control over environmental factors such as temperature, humidity, light, and nutrient levels, leading to healthier and more robust hemp plants. Additionally, the use of sustainable cultivation practices, including organic farming methods and renewable energy sources, can appeal to environmentally conscious consumers and contribute to a positive brand image for CBD companies.
Advancements in genetics and breeding techniques offer opportunities to develop hemp cultivars with desirable traits, such as higher CBD content, disease resistance, and faster growth rates. Through selective breeding and genetic engineering, researchers can tailor hemp varieties to meet the specific needs of CBD producers and consumers. For instance, breeding programs focused on increasing CBD levels while reducing THC (tetrahydrocannabinol) content can lead to the development of hemp strains that comply with regulatory standards and are well-suited for CBD extraction. The emergence of tissue culture technology allows for the rapid propagation of elite hemp clones, ensuring genetic uniformity and consistency in CBD production. Improved cultivation practices hold immense potential for driving innovation, efficiency, and sustainability within the CBD industry, positioning it for long-term growth and success.
Competitive Landscape Analysis
Key players in Global Cannabidiol (CBD) Market include,
- ENDOCA
- Cannoid, LLC
- Medical Marijuana, Inc.
- Folium Europe B.V.
- Canopy Growth Corporation
- Elixinol
- NuLeaf Naturals, LLC
- Isodiol International, Inc.
- PharmaHemp
- The Cronos Group
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Source
- Market Snapshot, By Product
- Market Snapshot, By Sales Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Cannabidiol (CBD) Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Growing Consumer Awareness and Acceptance
-
Increasing Scientific Research and Clinical Trials
-
Rising Demand for Natural and Organic Wellness Solutions
-
- Restraints
-
Regulatory Uncertainty
-
Product Quality and Standardization
-
Marketing and Advertising Restrictions
-
- Opportunities
-
Development of Pharmaceutical-Grade CBD Products
-
Delivery Method Advancements
-
Improved Cultivation Practices
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Cannabidiol (CBD) Market, By Source, 2021 - 2031 (USD Million)
- Hemp
- Marijuana
-
Cannabidiol (CBD) Market, By Product, 2021 - 2031 (USD Million)
-
CBD Oil
-
CBD Isolates
-
Others
-
- Cannabidiol (CBD) Market, By Sales Type, 2021 - 2031 (USD Million)
- B2B
- B2C
- Cannabidiol (CBD) Market, By End User, 2021 - 2031 (USD Million)
-
Medical
-
Personal Use
-
- Cannabidiol (CBD) Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Cannabidiol (CBD) Market, By Source, 2021 - 2031 (USD Million)
- Competitive Landscape Analysis
- Company Profiles
- ENDOCA
- Cannoid, LLC
- Medical Marijuana, Inc.
- Folium Europe B.V.
- Canopy Growth Corporation
- Elixinol
- NuLeaf Naturals, LLC
- Isodiol International, Inc.
- PharmaHemp
- The Cronos Group
- Company Profiles
- Analyst Views
- Future Outlook of the Market